Aurobindo Pharma gets Establishment Inspection Report for Telangana facility

09 Jan 2024 Evaluate

Aurobindo Pharma has received Establishment Inspection Report for Unit VI-B, classifying the facility as Voluntary Action Indicated (VAI). The U.S. Food and Drug Administration (USFDA) had conducted an inspection at the Unit VI-B, a Formulation manufacturing facility of the Company, situated at Chitkul Village, Patancheru Mandal, Sangareddy District, Telangana, from September 22 to September 29, 2023.  

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma Share Price

1257.30 16.60 (1.34%)
23-Dec-2024 11:20 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1822.50
Dr. Reddys Lab 1351.00
Cipla 1485.65
Lupin 2184.75
Zydus Lifesciences 978.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.